Blood transfusions and the subsequent risk of hematologic malignancies
Article first published online: 24 MAY 2010
© 2010 American Association of Blood Banks
Volume 50, Issue 10, pages 2249–2257, October 2010
How to Cite
Chang, C. M., Quinlan, S. C., Warren, J. L. and Engels, E. A. (2010), Blood transfusions and the subsequent risk of hematologic malignancies. Transfusion, 50: 2249–2257. doi: 10.1111/j.1537-2995.2010.02692.x
- Issue published online: 24 MAY 2010
- Article first published online: 24 MAY 2010
- Received for publication December 30, 2009; revision received March 5, 2010, and accepted March 11, 2010.
BACKGROUND: Blood transfusions are associated with viral transmission and immunomodulation, perhaps increasing subsequent risk of hematologic malignancies (HMs). Prior studies of transfusion recipients have lacked details on specific HM subtypes.
STUDY DESIGN AND METHODS: Risk of HM after blood transfusion was evaluated in a US population-based case-control study (77,488 elderly HM cases identified through cancer registries, 154,509 controls). Transfusions were identified using linked Medicare hospitalization claims. Polytomous logistic regression was used to calculate odds ratios (ORs) associating transfusion and HM subtypes by features suggestive of a causal relationship.
RESULTS: A history of transfusion was present in 7.9% of HM cases versus 5.9% of controls. Associations for most HM subtypes suggested reverse causality: ORs were elevated only during the shortest latency periods; ORs for unspecified anemia and gastrointestinal bleeding, which may be related to undiagnosed HM, were stronger than for surgeries, which are unlikely to be related to HM; and/or there was no dose response. In contrast, risk for lymphoplasmacytic lymphoma (1397 cases) was elevated at long latency (OR, 1.56 at 10+ years after transfusion), after transfusions related to surgeries (OR, 1.22-1.47), and in a dose-response relationship with number of transfusion-related hospitalizations (OR, 1.53 with one hospitalization; OR, 1.80 with two or more hospitalizations, p trend < 0.0001). Risk for marginal zone lymphoma (1915 cases) was also elevated at 10+ years after transfusion (OR, 1.80).
CONCLUSION: Consistent with prior studies, blood transfusions did not increase risk of most HM subtypes. Patterns of elevated risk for lymphoplasmacytic and marginal zone lymphomas suggest an etiologic role for transfusion.